Inloovi Ireland Ltd. (Clone)- Central Bank of Ireland Issues Warning on Unauthorised Firm

What Changed

• - The CBI has formally identified “Inloovi Ireland Ltd. (Clone)” as an unauthorised insurance intermediary that is not authorised to provide insurance intermediary or insurance distribution services in Ireland.
• The CBI has publicly associated specific digital identifiers with this fraudulent entity, including the website inloovi.com and email addresses insurance@inloovi.com, complaints@inloovi.com, noreply@inloovi.com, and hello@inloovi.com, which should no
• The CBI confirms that Inloovi Ireland Ltd. (Clone) has cloned details of a legitimate CBI‑authorised firm, A.R.B. Underwriting Limited t/a Buddy Travel Insurance, to deceive consumers, underscoring a recognised pattern of “clone firm” activity across
• The CBI clarifies that there is no connection whatsoever between the legitimate authorised entity and the clone firm, and the warning is intended to protect both consumers and the legitimate firm’s reputation.
• The CBI reiterates that the name of the unauthorised firm is published under Section 53 of the Central Bank (Supervision and Enforcement) Act 2013, reinforcing its supervisory and enforcement stance on unauthorised activities.
• The notice aligns with a broader CBI practice of publishing clone warnings across sectors (e.g., similar warnings on DEV Limited (Clone) in retail credit, Ireland Universal ICAV (Clone) in investments, and FTI Finance Limited (Clone)), signalling a c

Suggested Considerations

• Review and update internal sanctions/blacklist and fraud‑risk lists to include “Inloovi Ireland Ltd. (Clone)”, the domain inloovi.com, and the listed email addresses, ensuring screening across onboarding, claims, complaints, and payment processing.
• Conduct an immediate counterparty and referral review to confirm that no current or proposed distribution, outsourcing, or referral arrangements involve Inloovi Ireland Ltd. (Clone) or entities using the inloovi.com domain.
• Enhance KYC and intermediary due‑diligence procedures to include explicit checks against the CBI’s unauthorised firms list and Section 53 Warning Notices before entering into any new intermediary, coverholder, or introducer arrangement.
• Update staff training (particularly for sales, claims, complaints, and contact‑centre teams) on recognising clone‑firm indicators (e.g., similar names, use of look‑alike domains, unofficial email addresses) and on escalation pathways to compliance and fraud teams.
• Review and, where necessary, enhance website monitoring and brand‑abuse detection (including domain monitoring, phishing detection, and use of take‑down services) to identify and address fraudulent websites or email domains purporting to represent the firm.
• Integrate clone‑firm risk into the firm’s consumer protection and conduct risk assessments, including impacts on vulnerable customers, and document the control enhancements and board‑level reporting on this risk.

Key Dates

Who is Affected